The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy.

@article{Dragani2010TheCO,
  title={The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy.},
  author={Alfredo Dragani and Silvia Pascale and Antonio Recchiuti and Domenico Mattoscio and Stefano Lattanzio and Giovanna Petrucci and Luciana Mucci and Elisabetta Ferrante and Aida Habib and Franco Oreste Ranelletti and Giovanni Ciabattoni and Giovanni Dav{\'i} and Carlo Patrono and Bianca Rocca},
  journal={Blood},
  year={2010},
  volume={115 5},
  pages={
          1054-61
        }
}
We tested whether cyclooxygenase 2 (COX-2) expression and unacetylated COX-1 in newly formed platelets might contribute to persistent thromboxane (TX) biosynthesis in aspirin-treated essential thrombocythemia (ET). Forty-one patients on chronic aspirin (100 mg/day) and 24 healthy subjects were studied. Platelet COX-2 expression was significantly increased in patients and correlated with thiazole orange-positive platelets (r = 0.71, P < .001). The rate of TXA(2) biosynthesis in vivo, as… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 24 CITATIONS

Aspirin as antiplatelet agent in diabetes. PROS-.

  • European journal of internal medicine
  • 2010
VIEW 3 EXCERPTS
CITES BACKGROUND

Obesity and Altered Aspirin Pharmacology

  • Clinical Pharmacokinetics
  • 2017
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 51 REFERENCES

Molecular basis of diagnosis and treatment of polycythemia vera and essential thrombocythemia

AI Schafer
  • Blood
  • 2006
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Efficacy and 1060 DRAGANI et al BLOOD

R Landolfi, R Marchioli, J Kutti
  • For personal use only. on September
  • 2010